Referenser
Irish Cervical Screening Programme website (www.icsp.ie)
Department of Health & Children website (www.dohc.ie)
Baseman JG, Koutsky LA, The epidemiology of human papillomavirus infections. J Clin Virol 2005; 32S: S16-S24
Block SL, Nolan T, Sattler C et al Comparison of the Immunogenicity and Reactivity of a Prophylactic Quadrivalent Human Papillomavirus (Types 6, 11, 16 and 18) L1 Virus-Like Particle Vaccine in Male and Female Adolescents and Young Adult Women Pediatrics 118; 5 2135-2145
Bosch FX, de Sanjose S. Chapter 1: Human papillomavirus and cervical cancer - burden and assessment of causality. J Natl Cancer Inst Monogr 2003; 31: 3-13.
Bosch FX, Lorincz A, Munoz N, et al. The causal relation between human papillomavirus and cervical cancer. J Clin Pathol 2002; 55: 244-265.
Brown DR et al. J Infect Dis 2005; 191: 182-92
Burd E. Human papillomavirus and cervical cancer. Clin Microbiol Rev 2003;16:1-17.
Conway K. Attitudes to Papanicolaou smears. J Psychosom Obstet Gynecol 1996; 17: 189-194.
De Villiers EM et al. Virology 2004; 324: 17-27
Ferlay J, Bray P, Pizani P, Parkin DM. GLOBOCAN 2002: Cancer incidence, mortality and prevalence worldwide. IARC CancerBase No. 5, version 2.0. IARCPress, Lyon, 2004.
Franco EL, Harper DM. Vaccination against human papillomavirus infection: a new paradigm in cervical cancer control. Vaccine 2005; 23: 2388-2394.
Garland SM, Hernandez-Avila M, Wheeler CM et al Quadrivalent Vaccine Against Human Papillomavirus to Prevent Anogenital Diseases NEJM 2007 356; 19 1928-1943
Goldie SJ, Kohli M, Grima D, et al. Projected clinical benefits and cost-effectiveness of a human papillomavirus 16/18 vaccine. J Natl Cancer Inst 2004; 96: 604-615.
Kitchener HC et al. Vaccine 24S3 (2006): S3/63 - S3/70
Koutsky L. Epidemiology of genital human papillomavirus infection. Am J Med 1997; 102 (5A): 3-8.
Manhart LE et al. Sex Trans Dis 2002; 29(11): 725-35
McIntosh N, Human papillomavirus and cervical cancer. JHPIEGO Strategy Paper No. 8, May 2000.
Munoz N, Bosch FX, Castellsague X, et al. Against which human papillomavirus types shall we vaccinate and screen? The international perspective. Int J Cancer 2004; 111: 278-285.
Munoz N, Bosch FX, de Sanjose S et al. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Eng J Med 2003; 348: 518-27
Schiffman M, Kjaer SK. Chapter 2: Natural history of anogenital human papillomavirus infection and neoplasia. J Natl Cancer Inst Monogr 2003; 31: 14-19.
Stanley M. Immune responses to human papillomavirus. Vaccine 2006; 24 (Suppl1) S16-22
Walboomers JMM, Jacobs MV, Manos MM, et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 1999; 189: 12-19.
